Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
NCT Number: NCT05277948
Using a multi-center, large sample, randomized, patient-assessor blinded, sham-controlled clinical trial to evaluate the effect of thumbtack needle (TN) on ovarian function of patients with diminished ovarian reserve (DOR).
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Not applicable
Wuhan, Hubei, 430030, China
Diminished ovarian reserve (DOR) is the precursor state of ovarian failure, and can cause the decline of women's reproductive function. Some studies have demonstrated that acupuncture can improve ovarian reserve function. Thumbtack needle (TN), as a kind of acupuncture, is a form of long-term indwelling intradermal needle therapy. TN has been found effective in treating DOR in our clinic. In this study, a multi-center, large sample, randomized, patient-assessor blinded, sham-controlled clinical trial was used to evaluate the effect of TN on ovarian reserve function of patients with diminished ovarian reserve (DOR).
First, patients will be recruited according to the inclusion criteria and exclusion criteria.
Second, baseline measurements (including ovarian reserve function, blood biochemical index, scores from the self-rating anxiety and depression scale, quality of life, sleep status) will be taken.
Third, each patient will receive the treatment of TN or sham TN for a total of 2 menstrual cycles.
Fourth, the above baseline measurements will be taken again as soon as the treatment is finished and outcome measures will be recorded after the treatment.
Last, Natural pregnancy outcomes includes natural pregnancy rate (including biochemical pregnancy rate, clinical pregnancy rate) and miscarriage rate during the treatment period and within 6 months after treatment completion will be followed up. Pregnancy outcome Includes number of oocytes retrieved, fertilization rate, embryo formation rate, blastocyst formation rate, biochemical pregnancy rate, clinical pregnancy rate and miscarriage rate during IVF-ET within 6 months after treatment completion will also be followed up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight acupoints of CV4, CV3, SP6, ST36 and BL23 will be treated by disposable sterile thumbtack needle (TN) for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four acupoints of bilateral ovary acupoints and bilateral EX-B7 will be treated by disposable sterile electro-thumbtack needle (ETN) (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY) with pulsed electrical stimulation.
The patients will receive a treatment of 2 menstrual cycles.
The acupoints used in the control group are the same as those in the treatment group. Eight points of CV4, CV3, SP6, ST36 and BL23 will be treated by the sterile sham thumbtack needle (TN) for single use (Hangzhou Zhuomai Medical Technology Co., LTD.), and four points of bilateral ovary acupoints and bilateral EX-B7 will be treated by disposable sterile sham electro-thumbtack needle (ETN) (Hangzhou Zhuomai Medical Technology Co., LTD.) with sham pulsed electrical stimulation.
The sham TN and ETN used in this group are identical in appearance, shape, and color to the active TN and ETN but lack the needle body, thus lacking the needle-penetrating effect. The stimulation method and frequency for the sham ETN are the same as those of the ETN group. The only difference is that the electrode pads used in the sham ETN group are specially designed as insulated controls.
The patients will receive a treatment of 2 menstrual cycles
Time frame: 0 week and up to 4 weeks after treatment completion
Assessing patients' serum level of AMH in ng/ml at baseline (0 week) and immediately (up to 4 weeks) after treatment completion.
Time frame: 0 week and up to 4 weeks after treatment completion
Counting the number of ovarian antral follicle count (AFC) on the second day of menstruation at baseline (0 week) and immediately (up to 4 weeks) after treatment completion.
Time frame: 0 week and up to 4 weeks after treatment completion
Evaluating the serum levels of sex hormones (FSH, LH, E2, P, T, and PRL) on the second day of menstruation at baseline and immediately (up to 4 weeks) after treatment completion.
Time frame: 0 week and within 6 months after treatment completion
Natural pregnancy outcomes include natural pregnancy rate (including biochemical pregnancy rate, and clinical pregnancy rate) and miscarriage rate during the treatment period and within 6 months after treatment completion.
Time frame: 0 week and within 6 months after treatment completion
Pregnancy outcomes Include number of oocytes retrieved, fertilization rate, embryo formation rate, blastocyst formation rate, biochemical pregnancy rate, clinical pregnancy rate, and miscarriage rate during IVF-ET within 6 months after treatment completion.
Time frame: within 6 months after treatment completion
Observing follicular fluid level of transforming growth factor β (TGF β) when patients undergoing IVF/ICSI
-ET after the treatment.
Time frame: within 6 months after treatment completion
Observing follicular fluid level of TNF-α when patients undergoing IVF/ICSI
-ET after the treatment.
Time frame: within 6 months after treatment completion
Observing follicular fluid level of ROS when patients undergoing IVF/ICSI
-ET after the treatment.
Time frame: within 6 months after treatment completion
Observing follicular fluid level of SOD when patients undergoing IVF/ICSI
-ET after the treatment.
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood corticotropin-releasing hormone (CRH) at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood norepinephrine at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood 5-hydroxytryptamine (5-HT) at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood beta-aminobutyric acid (GABA) at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood dopamine (DA) at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Observing the level of blood neuro-endorphin (β-ET) at baseline and immediately after treatment
Time frame: 0 week and up to 4 weeks after treatment completion
Anxiety status will be assessed using Zung anxiety self-rating scale (Zung-SAS) at baseline and immediately after treatment.
Time frame: 0 week and up to 4 weeks after treatment completion
Depression status will be assessed using Zung depression self-rating scale (Zung-SDS) at baseline and immediately after treatment.
Time frame: 0 week and up to 4 weeks after treatment completion
Quality of life will be assessed by SF-36 at baseline and immediately after treatment..
Time frame: 0 week and up to 4 weeks after treatment completion
Sleep status will be evaluated using Pittsburgh sleep quality index (PSQI) at baseline and immediately after treatment.
Time frame: 0 week and up to 4 weeks after treatment completion
Untargeted metabolomics levels in patient serum before and after treatment.
Time frame: During IVF-ET within 6 months after study completion
Observing untargeted metabolomics levels in follicular fluid collected from patients undergoing IVF/ICSI-ET cycle after treatment completion
Time frame: During IVF-ET within 6 months after study completion
Proteomic analysis of granulosa cells collected during IVF-ET cycles after treatment.
Dongmei Huang
Other
Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR): A Randomized Controlled Clinical Trial
Acronym: TN-DOR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07249411
Diminished Ovarian Reserve
Caracas, Venezuela
View Trial DetailsNCT04275700
Diminished Ovarian Reserve, Ovarian Failure
New York, United States
View Trial DetailsNCT05677828
Diminished Ovarian Reserve, Genital Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT04237909
Adnexal Diseases, Diminished Ovarian Reserve
Istanbul, Turkey (Türkiye)
View Trial Details